{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:58:27Z","timestamp":1790834307714,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS127984"],"award-info":[{"award-number":["R01NS127984"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.omton.2024.200808","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T23:43:27Z","timestamp":1714002207000},"page":"200808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["BRAF V600E in a preclinical model of pleomorphic Xanthoastrocytoma: Analysis of the tumor microenvironment and immune cell infiltration dynamics in\u00a0vivo"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0141-7399","authenticated-orcid":false,"given":"Alessandro","family":"Canella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Nazzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mykyta","family":"Artomov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi Prakruthi","family":"Rao Venkata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Lyberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr","family":"Ukhatov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao Lulu","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Behbehani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nduka M.","family":"Amankulor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Katharina","family":"Petritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajwal","family":"Rajappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2024.200808_bib1","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.omton.2024.200808_bib2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/neuonc\/noq178","article-title":"Survival and long-term health and cognitive outcomes after low-grade glioma","volume":"13","author":"Armstrong","year":"2011","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.omton.2024.200808_bib3","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/pbc.24958","article-title":"Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database","volume":"61","author":"Bandopadhayay","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omton.2024.200808_bib4","article-title":"Response and resistance to BRAFV600E inhibition in gliomas: Roadblocks ahead?","volume":"12","author":"Capogiri","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2024.200808_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100857","article-title":"Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era","volume":"36","author":"Manoharan","year":"2023","journal-title":"Neoplasia"},{"key":"10.1016\/j.omton.2024.200808_bib6","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1200\/JCO.2016.71.8726","article-title":"Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas","volume":"35","author":"Lassaletta","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omton.2024.200808_bib7","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1158\/2159-8290.CD-17-1263","article-title":"A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAF(V600E)-Mutant Brain Tumor","volume":"8","author":"Wang","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2024.200808_bib8","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fonc.2015.00054","article-title":"Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas","volume":"5","author":"Penman","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2024.200808_bib9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00401-011-0802-6","article-title":"Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma","volume":"121","author":"Schindler","year":"2011","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.omton.2024.200808_bib10","doi-asserted-by":"crossref","first-page":"Cns39","DOI":"10.2217\/cns-2019-0009","article-title":"Pleomorphic xanthoastrocytoma: a brief review","volume":"8","author":"Shaikh","year":"2019","journal-title":"CNS Oncol."},{"key":"10.1016\/j.omton.2024.200808_bib11","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.2014.58.3922","article-title":"BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma","volume":"33","author":"Mistry","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omton.2024.200808_bib12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1158\/1535-7163.MCT-10-0799","article-title":"BRAFV600E: implications for carcinogenesis and molecular therapy","volume":"10","author":"Cantwell-Dorris","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omton.2024.200808_bib13","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/cncr.29907","article-title":"Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: A population-based study","volume":"122","author":"Krishnatry","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.omton.2024.200808_bib14","doi-asserted-by":"crossref","first-page":"8710","DOI":"10.1073\/pnas.1117255109","article-title":"Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy","volume":"109","author":"Huillard","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2024.200808_bib15","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1073\/pnas.1219232110","article-title":"Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas","volume":"110","author":"Sievert","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2024.200808_bib16","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2024.200808_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11060-020-03483-y","article-title":"Immune suppression in gliomas","volume":"151","author":"Grabowski","year":"2021","journal-title":"J.\u00a0Neurooncol."},{"key":"10.1016\/j.omton.2024.200808_bib18","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic Targeting of the Tumor Microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2024.200808_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112197","article-title":"Single-cell RNA sequencing reveals immunosuppressive myeloid cell diversity during malignant progression in a murine model of glioma","volume":"42","author":"Rajendran","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2024.200808_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112891","article-title":"Genetically modified IL2 bone-marrow-derived myeloid cells reprogram the glioma immunosuppressive tumor microenvironment","volume":"42","author":"Canella","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2024.200808_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2020.101515","article-title":"Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapy","volume":"34","author":"Griffin","year":"2020","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.omton.2024.200808_bib22","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1101\/gad.294991.116","article-title":"Mutant IDH1 regulates the tumor-associated immune system in gliomas","volume":"31","author":"Amankulor","year":"2017","journal-title":"Genes Dev."},{"key":"10.1016\/j.omton.2024.200808_bib23","article-title":"Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition","volume":"4","author":"Nobre","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.omton.2024.200808_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1223199","article-title":"Successes and challenges in modeling heterogeneous BRAF(V600E) mutated central nervous system neoplasms","volume":"13","author":"Xing","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2024.200808_bib25","doi-asserted-by":"crossref","first-page":"75839","DOI":"10.18632\/oncotarget.12419","article-title":"Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model","volume":"7","author":"Grossauer","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2024.200808_bib26","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41587-020-0472-9","article-title":"Multiplex digital spatial profiling of proteins and RNA in fixed tissue","volume":"38","author":"Merritt","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omton.2024.200808_bib27","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/ni.3006","article-title":"High-dimensional analysis of the murine myeloid cell system","volume":"15","author":"Becher","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omton.2024.200808_bib28","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1101\/gad.12.23.3675","article-title":"A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice","volume":"12","author":"Holland","year":"1998","journal-title":"Genes Dev."},{"key":"10.1016\/j.omton.2024.200808_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1593\/tlo.09100","article-title":"Modeling Adult Gliomas Using RCAS\/t-va Technology","volume":"2","author":"Hambardzumyan","year":"2009","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.omton.2024.200808_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2023.102094","article-title":"Inducing primary brainstem gliomas in genetically engineered mice using RCAS\/TVA retroviruses and Cre\/loxP recombination","volume":"4","author":"Weidenhammer","year":"2023","journal-title":"STAR Protoc."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032992400050X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032992400050X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:19:19Z","timestamp":1765804759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S295032992400050X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S295032992400050X"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2024.200808","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRAF V600E in a preclinical model of pleomorphic Xanthoastrocytoma: Analysis of the tumor microenvironment and immune cell infiltration dynamics in\u00a0vivo","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2024.200808","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"200808"}}